State AGs Pen EpiPen Settlements With Mylan

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • Maryland AG Anthony Brown and North Carolina AG Jeff Jackson announced separate settlements with Mylan resolving allegations that the company used anticompetitive tactics to maintain EpiPen’s market dominance and drive up prices for the life-saving allergy medication.
  • According to the AGs’ offices, Mylan allegedly suppressed generic competition through exclusionary contracts with pharmacy benefit managers, delayed lower-cost competitors, made misleading or unfounded claims about competing products, and required consumers to buy two-packs they did not always need.
  • North Carolina’s settlement also resolves allegations that Mylan misclassified EpiPen under the Medicaid Drug Rebate Program.
  • Under the settlements, Maryland received $4.5 million and North Carolina received $11 million; Mylan also agreed to increase its co-pay coupon for the authorized generic version of EpiPen from $25 to $40.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Cozen O'Connor

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance

Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide